ANTEJIN BIOTECH
Antejin Biotech specializes in developing rabies immunogenic conjugate useful for preparing rabies conjugate vaccine.
ANTEJIN BIOTECH
Industry:
Biotechnology
Address:
Chengdu, Sichuan, China
Country:
China
Status:
Active
Similar Organizations
Oligogen
Oligogen is a bio-venture that specializes in drug development using stem cell technology.
More informations about "Antejin Biotech"
Chengdu Antejin Biotech Co. - PitchBook
Chengdu Antejin Biotech Co. General Information Description. Developer of vaccines based in Chengdu, China. The company specializes in developing rabies immunogenic conjugate …See details»
Fosun Pharma acquires Antejin Biotech - 2021-10-28 - Crunchbase
Acquired Organization: Antejin Biotech Antejin Biotech specializes in developing rabies immunogenic conjugate useful for preparing rabies conjugate vaccine. Acquiring Organization: …See details»
Chengdu Antejin Biotech - Products, Competitors, Financials, …
Chengdu Antejin Biotech is a biotechnology company that produces pneumonia, tetanus, rabies, and other vaccines. It is based in Chengdu, Sichuan. On October 28th, 2021, Fosun …See details»
Antejin Biotech - Company Profile - Tracxn
Oct 21, 2024 Antejin Biotech - Provider of bacterial vaccine development and pharmaceutical services. Acquired by Fosun Pharmaceutical. Antejin Biotech has 36 competitors.See details»
Fosun Apexvac (Dalian) Biopharmaceutical Co., Ltd.
Nov 1, 2024 The Shanghai-based company has bought a majority stake in Chengdu Antejin Biotech, which is developing a shot against 13 strains of pneumonia-causing bacteria, making …See details»
Fosun Pharma acquires vaccine firm Antejin in deal worth up to …
Oct 28, 2021 Fosun Pharmaceutical Group Co. Ltd. has acquired a 73% stake of Antejin Biotech Co. Ltd. in a merger and acquisition deal worth up to ¥4.006 billion (US$626.2 million) to …See details»
Chengdu Antejin Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Explore Chengdu Antejin Biotechnology Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 1 news, Disease Domain:Infectious Diseases, …See details»
Antejin Biotech - Crunchbase
Antejin Biotech specializes in developing rabies immunogenic conjugate useful for preparing rabies conjugate vaccine.See details»
Antejin Biotech Co Ltd - Drug pipelines, Patents, Clinical trials
Explore Antejin Biotech Co Ltd with its drug pipeline, therapeutic area, technology platform, . Data. Feature. Plans. Sign Up for Free. Request Demo. Sign Up for Free. Last update 02 May …See details»
Antejin Biotech Co. Ltd. | BioWorld
Aug 27, 2024 Fosun Pharmaceutical Group Co. Ltd. has acquired a 73% stake of Antejin Biotech Co. Ltd. in a merger and acquisition deal worth up to ¥4.006 billion (US$626.2 million) …See details»
Fosun Pharma acquires vaccine firm Antejin in deal worth up
Fosun Pharmaceutical Group Co. Ltd. has acquired a 73% stake of Antejin Biotech Co. Ltd. in a merger and acquisition deal worth up to ¥4.006 billion (US$626.2 million) to expand its pipeline …See details»
Fosun Antejin - PitchBook
Fosun Antejin was founded in 2012. Where is Fosun Antejin headquartered? Fosun Antejin is headquartered in Chengdu, China. What is the size of Fosun Antejin? Fosun Antejin has 600 …See details»
Fosun Announces $628 Million Deal for Majority Stake in Chengdu …
Shanghai Fosun Pharma announced a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company. Fosun paid $174 million to nine Antejin shareholders, and …See details»
Week in Review: Fosun Pharma Acquires Majority Stake in China …
Oct 30, 2021 Deals and Financings Shanghai Fosun Pharma will buy a 73% stake in Chengdu Antejin Biotech, a vaccine company, for $628 million -- $174 million in cash plus its vaccine …See details»
Fosun Announces $628 Million Deal for Majority Stake in Chengdu …
On October 27, 2021 Shanghai Fosun Pharma reported a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company (Press release, Fosun Pharma, OCT …See details»
23-valent pneumococcal polysaccharide vaccine (Chengdu Antejin)
23-valent pneumococcal polysaccharide vaccine (Chengdu Antejin): a Immunostimulants Drug, Initially developed by Chengdu Antejin Biotechnology Co., Ltd., Now, its global highest R&D …See details»
Fosun Pharma - Funding, Financials, Valuation & Investors
Which industries has this organization had the most exits in? Show . Butterfly Network Butterfly Network designs a medical imaging device that reduces the cost of real-time and three …See details»
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZEâ„¢ (lazertinib) …
1 day ago Janssen Research & Development, LLC, and Janssen Biotech, Inc., are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release …See details»
13-valent pneumococcal conjugate vaccine(Fosun Adgenvax
Chengdu Antejin Biotechnology Co., Ltd. ChiCTR2300077384 / Recruiting Phase 3 IIT Phase III clinical trial to evaluate the immunogenicity and safety of 13-valent pneumococcal conjugate …See details»
Drug Company to Share Revenues With Indigenous People Who …
1 day ago Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. Listen to this article · 7:34 …See details»